The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is a huge mover today! The stock increased 3.98% or $0.79 on November 23, hitting $20.65. About 268,717 shares traded hands. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has risen 57.51% since April 22, 2016 and is uptrending. It has outperformed by 52.10% the S&P500.
The move comes after 8 months positive chart setup for the $938.58M company. It was reported on Nov, 24 by Barchart.com. We have $21.68 PT which if reached, will make NASDAQ:AMPH worth $46.93 million more.
Analysts await Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to report earnings on March, 13.
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Ratings Coverage
Out of 4 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Amphastar Pharmaceuticals has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Friday, February 19 by Wells Fargo. Zacks downgraded the stock to “Buy” rating in Monday, August 10 report. The firm earned “Hold” rating on Tuesday, August 18 by Zacks. The stock has “Buy” rating given by Needham on Tuesday, May 10. The stock has “Market Perform” rating given by BMO Capital Markets on Wednesday, June 29. The firm earned “Buy” rating on Tuesday, January 19 by Jefferies. The rating was maintained by Jefferies on Tuesday, August 9 with “Buy”.
According to Zacks Investment Research, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.”
Insitutional Activity: The institutional sentiment increased to 3.17 in 2016 Q2. Its up 1.07, from 2.1 in 2016Q1. The ratio is positive, as 7 funds sold all Amphastar Pharmaceuticals Inc shares owned while 23 reduced positions. 19 funds bought stakes while 44 increased positions. They now own 15.47 million shares or 11.85% more from 13.83 million shares in 2016Q1.
Tfs Cap Ltd Liability Com accumulated 0.14% or 46,859 shares. C M Bidwell & Assoc Ltd has 0.05% invested in the company for 12,820 shares. Massachusetts Financial Ma holds 45,886 shares or 0% of its portfolio. Bluestein R H & owns 20,000 shares or 0.02% of their US portfolio. Manufacturers Life Insur The last reported 0% of its portfolio in the stock. Moreover, Winslow Evans And Crocker has 0% invested in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for 766 shares. Creative Planning holds 0% of its portfolio in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for 25,948 shares. Invesco Ltd reported 20,089 shares or 0% of all its holdings. Dimensional Fund Advsrs L P owns 361,010 shares or 0% of their US portfolio. Parametric Port Associates Ltd Co holds 0% or 57,345 shares in its portfolio. Citigroup last reported 13,089 shares in the company. The Texas-based Hbk Lp has invested 0% in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Envestnet Asset Mngmt holds 0% of its portfolio in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for 9,622 shares. Geode Ltd Liability Com owns 298,297 shares or 0% of their US portfolio. Tower Research Cap (Trc) has 0% invested in the company for 1,123 shares.
Another recent and important Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) news was published by Fool.com which published an article titled: “Why Amphastar Pharmaceuticals, Inc. is Soaring Today” on September 20, 2016.
AMPH Company Profile
Amphastar Pharmaceuticals, Inc., incorporated on May 19, 2004, is a specialty pharmaceutical company. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment makes, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment makes and distributes recombinant human insulin and porcine insulin. The Firm makes and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.